Dallas, TX -- (SBWIRE) -- 11/08/2011 -- Product Profiles: Depression- Next generation vies for second-line patients – Depression treatment market

ReportsnReports.com adds :Datamonitor Research Report: Product Profiles: Depression: Next generation vies for second-line patients :Depression treatment market: to its store.

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Features and benefits

Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating depression.

Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.

Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.

Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.

Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Highlights

Datamonitor's physician survey reveals that psychiatrists perceive Forest's and Lundbeck's selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.

TC-5214 (Targacept/AstraZeneca) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.

Forest's Viibryd (vilazodone) has the hallmarks of a new blockbuster: a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel:+ 1 888 391 5441
E-mail: sales@reportsandreports.com